Anaplastic large cell lymphoma (ALCL) is a heterogeneous family of lymphoid tumours, among which the T and null cell types were recently listed in the REAL classification as a distinct entity. Reports on autologous stem cell transplantation (ASCT) in this group are only occasional. Sixty-four patients with T and null cell ALCL from 25 European centres had been registered with the European Group for Blood and Marrow Transplantation (EBMT) at the onset of this study. The median age was 25 years (range 3.2-53.0). Thirty of the 64 patients (47%) were in complete remission (CR), 18 (28%) in partial remission (PR), and the remaining 16 (25%) had a more advanced or chemotherapy-refractory disease at transplant. Eighty-one percent of the patients were conditioned with chemotherapy alone and 75% received marrow stem cells. All the patients transplanted in first CR (15), except one, maintained the CR over time; six of 15 transplanted in CR subsequent to first, six of 18 transplanted in PR and 14 of 16 transplanted in refractory or relapsed disease progressed. Actuarial overall survival (OS) at 10 years is 70%. Multivariate analysis showed that good status at transplant, younger age, absence of B symptoms and absence of extranodal disease indicated a better prognosis. These data suggest that ASCT should be considered as a possible treatment for chemosensitive patients in CR or PR. However, definitive conclusions cannot be drawn from this study and a prospective randomised trial between ASCT and conventional chemotherapy may be indicated. Keywords: anaplastic large cell lymphoma; autologous stem cell transplantation
of the cases, with some recent series showing up to 90% of complete remissions. [1] [2] [3] [4] [5] [6] [7] [8] Relapse rate ranges widely from 25 to 45%, with less than 50% of patients alive and free of disease at a median observation time from diagnosis no longer than 36 months. [1] [2] [3] [4] [5] [6] [7] [8] The different behaviour in relapse rate may reflect the existence of a heterogeneous family of diseases: ALCL T and null cell common type, ALCL T and null cell Hodgkin-like and diffuse anaplastic large B cell lymphoma. 9, 10 These three major entities probably have different prognosis and outcome, but this is not clearly underlined in the papers already published on this subject. 11, 12 It is surprising that although the clinical, histological and immunophenotypic characteristics indicate that this lymphoma may be a group of aggressive lymphoid tumours, reports on autologous stem cell transplantation (ASCT) in ALCL are occasional, and mainly refer to cases in relapse. 1, 2, 4, 5 It was recently shown, in a study performed on a small monocentric series, that primary systemic CD30-positive ALCL of the adults is a curable disease when ASCT is performed as part of first-line treatment. 13, 14 In this study patients with B cell ALCL were included.
The REAL classification defines T and null cell ALCL as a distinct entity with a fairly good prognosis. 10 To understand the relevance that the inclusion of this lymphoma had for the good results obtained in the monocentric study mentioned above, we have studied 64 patients affected by T and null cell ALCL autotransplanted and registered with the European Group for Blood and Marrow Transplantation (EBMT) between 1983 and 1996.
Patients and methods
EBMT centres were asked to submit information on all patients with NHL who had been reclassified or newly classified, using the REAL criteria, as T and null cell ALCL and who had been subjected to autologous transplantation between 1983 and 1996. No attempt was made to review the histology centrally. All centres which participated in the study are contributors of lymphoma cases to the EBMT and possess reliable histopathology laboratories (see Acknowledgements).
The information requested was: sex, age, histology, phenotype, performance status (ECOG scale), 15 B symptoms, nodal involvement, bulk, number and sites of extranodal disease, Ann Arbor stage, LDH, chemotherapy program, radiotherapy, status at transplant, months from diagnosis to ASCT and from ASCT to present, stem cell source, conditioning regimen, response at 90 days, relapse or progression after ASCT, current status, date of death and date of progression/relapse if applicable.
Disease status was defined as follows: complete remission (CR) as no evidence of disease after treatment; partial remission (PR) as less than 50% residual disease as compared to pre-treatment. Refractory disease was defined as no effect of treatment or a decrease in disease load following treatment of less than 50%. Responding relapse refers to patients with relapsed disease whose disease has responded to salvage chemotherapy prior to transplant.
Statistics
Overall survival (OS) was calculated from the date of transplantation to death or last date seen. Progression-free survival (PFS) was calculated from date of transplantation to date of progression if the patient progressed, or to date of death or last date seen if the patient did not progress. The Kaplan and Meier method was employed to estimate survival; 16 the log-rank test to detect significant differences. Multivariate analysis was performed on possible prognostic factors using the Cox model. 17 Proportionality of hazards was tested using standard graphical methods. The ageadjusted international prognosis index (AAIPI) was calculated for all patients for which the information was available.
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Results
A total of 64 patients referred from 25 European centres was included in the study. Patient details regarding characteristics at diagnosis and response to first-line treatment are reported in Table 1 .
Clinical features
Median age at diagnosis was 25 years with 18 patients younger than 20 years. Sixty-four percent of the patients presented with advanced stage disease (III + IV). In about 60% of them a mediastinal involvement (with bulky mass in about 25% of the cases) was documented; as expected, bone marrow involvement was occasional. The AAIPI was calculated for 70% of the patients, with more than half of these patients in the low risk category (AAIPI 0 and 1). Sixty-four percent of patients below 20 were in the high risk category (AAIPI 2 and 3) compared to only 19% in older patients (Fischer exact test, P Ͻ 0.01).
First line treatment and status at transplant
First-line therapy was based on chemotherapy alone in more than 90% of the cases with only three patients being irradiated before ASCT and none after. A response was obtained or maintained in more than 75% of the patients Table 1 Characteristics of the patients at diagnosis with a CR rate of 50% (details are shown in Table 1 ). The median interval time between diagnosis and transplant was 9.6 months (range 3.6-94.6). Status at transplant is detailed in Table 2 : 30 of 64 patients (47%) were transplanted in CR, but only 15 in first CR (23% of the total number). Thirty of the 64 cases (47%) responsive to first-line therapy (CR + PR) were transplanted as consolidation shortly after the end of CHT. The majority of the patients were conditioned with CHT alone (81%) and were reinfused with bone marrow stem cells (75%). status at transplant and current status. All the patients (n = 30) transplanted in CR maintained it at 90 days. Complete remission was achieved for 44% of the patients transplanted in PR and for 50% of the patients transplanted in sensitive relapse. None of those with refractory disease obtained a CR (Table 3a) . With respect to the most recent status, one patient transplanted in first CR (7%), six (40%) of those transplanted in у2nd CR, six (33%) of those transplanted in PR and seven (87%) of those transplanted in sensitive relapse progressed (Table 3b) .
Response to treatment
Outcome
Median follow-up of the patients in these series is 43.3 months. OS of the whole population (n = 64) at 2 years, 5 years and 10 years was 76.3%, 70.3% and 70.3% respectively ( Figure 1) . PFS for all patients was 62.4%, 56.4% and 47.0% at 2, 5 and 10 years, respectively, with the median at 83.6 months (Figure 1 ). Eighteen patients aged less than 20 years were transplanted. OS was significantly better (P = 0.032) than that of the adult population (in fact all patients but one under 20 years are still alive) (Figure 2 ), but there was no difference in PFS (P Ͼ 0.4). Figure 3 shows the outcome (OS) in relation to status at transplant: dividing the patients into four groups (1st CR , 1st PR, other responders and refractory/relapsed) a statistically significant difference emerges (P = 0.006). The outcome at 5 years for patients transplanted in 1st PR and for other responders is similar.
Multivariate analysis showed that age at transplant, number of extranodal sites at diagnosis, presence of symptoms at diagnosis and status at transplant were predictive of survival (Table 4a) . Type of transplant, with PBSC doing worse than BM, symptoms at diagnosis, number of extranodal sites and status at transplant were predictive for PFS (Table 4b ). The AAIPI was of no prognostic value in the prediction of survival or PFS in this group either in multivariate analysis or univariate analysis.
Discussion
In 1997, the non-Hodgkin's Lymphoma Classification Project published a retrospective analysis on 1403 cases of NHL to validate the clinical significance of the different entities identified by the REAL classification. All types of T cell lymphomas made up only 12% of the cases, with only 2.4% of ALCL. 11 Harris in 1996 19 reported a relative frequency of ALCL in USA and Europe of 5% among lymphomas of the adults and 15% among those of children. These data confirm that this is a small group of lymphomas and could partially explain the paucity of reports on ALCL and ASCT found in the literature. Moreover the majority of the papers published up to now combined the T and null cell and the B cell phenotypes that are currently considered as different clinical entities. 10 In this report we concentrate on the T and null cell phenotype. Although no central histology review was performed, we have no reason to believe that the histologies were in error: all centres involved characterise and treat lymphomas regularly, and the accuracy of diagnosis using histology and immunophenotyping for this group of lymphomas is considered to be of 85%. 11 It is considered that ALCL does well with conventional therapy and ASCT is not regularly offered to patients with this disease. A review of the literature, however, seems to indicate that the outcome of patients who responded partially or were resistant to first-line therapy and of patients relapsing after the attainment of a CR is not good. In the papers published in the last 5 years 1-7 the percent of partial responders is always between 10 and 20%. In the paper by Filippa et al, 5 out of six partially responding patients, five died and one obtained a CR after ASCT. Longo et al 3 emphasised that the only significant prognostic factor was the response to initial therapy with an OS at 3 years of patients in CR of 89% vs only 38% of PR/refractory. Penny 8 reported three deaths out of six PR. In all these cases, the longest observation period from diagnosis was less than 2 years. The conclusion is that patients who only respond partially to first-line chemotherapy do not do well.
The prognosis of relapsed patients is also not good: Penny et al 8 reported four deaths out of seven relapses, of which two had obtained a first CR with conventional chemotherapy; Longo et al 3 two out of three; Filippa, 5 who presented a detailed history of each patient, documented 15 relapses out of 36 patients with an initial CR to chemotherapy. Of these relapses, five (33%) were treated with conventional chemotherapy and were alive at the time of publication although not all were free from disease; seven (47%) died, and three (20%) were treated with ASCT and were alive without disease at the time of publication (longest observation period 80 months). These data indicate not only the poor prognosis of relapsed patients but the fairly high incidence of relapses in patients who achieve a CR with conventional chemotherapy.
With respect to the series of patients in our study, 30 (46.1%) of them received the procedure in CR with only 15 (23%) in first CR. Forty-nine out of 64 patients (76%) were responding to CHT at the time of transplant. This does not reflect the population that is normally treated with conventional chemotherapy stressing that the Registry population is biased towards a higher frequency of worse prognosis patients.
ASCT demonstrated a capacity to improve the quality of the response with a conversion rate of 44% from PR to CR. Moreover the CR rate obtained with transplant was maintained. This means that patients with PR after first-line treatment did better than those reported in the literature. ASCT may also have consolidated the response in more than 50% of the patients who were transplanted in CR subsequent to first. OS for patients in CR at 90 days post-ASCT was 91.8% at 2 years; the 10 years projected PFS was 70.7%. The curves tend to a plateau after 24 months (only one event after this time) confirming that no deaths or relapses are expected after that time-point for these patients, as already published by others. 20 Transplant does not apparently change the quality of response in the group of refractory/resistant and relapsed patients and 13 of the 16 reported deaths happened in this group.
In support of the possible role of ASCT in salvaging chemosensitive patients, it has recently been reported that a program of sequential intensive treatment that includes CHT Ϯ RT and ASCT as first-line therapy in responding patients (CR + PR) induces a CR rate close to 100% and prevents early relapses, projecting all these patients as longterm survivors. 13, 14 The series of ALCL treated with ASCT reported in our study has the longest period of follow-up ever published, with a median observation time from transplant of 3.6 years (range 3 months-10 years). The actuarial overall survival of 70.3% (95% CI: 56.1-81.5) at 10 years, given the worse stage of disease presented by our patients, seems to be in excess of what is reported in the literature for patients treated with conventional chemotherapy (projected followup of 5 years). 6 The outcome of the group under study in the current report could not be predicted from the AAIPI at diagnosis. This lack of applicability of the AAIPI for the T and null cell ALCL is also described in the clinical evaluation that the International Lymphoma Study Group did of NHL 11 and is not surprising. In addition, it is not clear that an index developed from lymphoma patients undergoing conventional treatment needs be relevant in the ASCT setting.
In our series 18 patients were younger than 20 years, confirming that T and null cell ALCL are more frequent among paediatric and young patients. The survival of this group of patients is significantly superior, while PFS curves are identical, suggesting that age does not change the sensitivity but probably affects the endurance to the treatment. Age did not influence the outcome of patients who showed a CR 90 days post-ASCT. Younger patients tended to belong to the high risk category as calculated through the AAIPI despite doing better, further demonstrating the lack of applicability of this index for this group of lymphomas.
Multivariate analysis showed that, aside from status at transplant, other variables also have a predictive value for OS and PFS: age with survival, symptoms and number of extranodal sites with both survival and PFS. The better PFS of those transplanted with BM rather than with PBSC stem cells is not easy to interpret, and would require further studies with a larger population.
In conclusion these data seem to indicate that ASCT should be be considered as a possible therapy for ALCL in complete remission subsequent to first and patients responding partially to first-line chemotherapy. If given as consolidation, it may also prevent the high level of relapse seen until now in patients in first complete remission. Nevertheless definitive conclusions about the superiority or otherwise of high-dose therapy in first-line treatment can only be made through prospective randomised trials.
